Navigation Links
Pharmaco in Zambia Scrutinizes the Side Effects of Medicines Launched In the Market

A new vigilant body was set up by the Zambia Pharmaceutical Regulatory Authority (PRA). The main purpose of this body is to monitor the safety of medicines during the post marketing// surveillance process. Pharmaco, as the monitoring body is named would supervise all adverse reactions due to a particular drug. This is to inculcate in people the rational use of medicines. The acting Health Minister Ronnie Shikapwasha launched the body on the 16th of June said that this unit would efficiently perform the job allotted to it. He also said that this was launched as adverse effects of all drugs that hit the market are not known before the medicine is marketed.

Hence this body would create awareness among he public. He said that in the recent years there was an increase in the use of medicine for HIV/AIDS, malaria and tuberculosis and hence there was a need for the monitoring unit. These drugs were new to the market and sufficient safety data was not available. This led to the development of a monitoring system which would study the effects of the drugs, documenting drug resistance patterns and treatment failures of both conventional and new medicines. In conclusion this would always keep the public as well as the medical community posted about the medicines in the market.


'"/>




Page: 1

Related medicine news :

1. India, US Pharmacopoeia Signs Mou to Promote Awareness About Medicines
2. Herbal remedies to be tested by Zambia for AIDS treatment
3. Bird Flu In Zambia-Panic Among Locals
4. Zambia Struggling To Identify AIDS Sufferers
5. The Aids Programme In Zambia Reported As A Success
6. PEPFAR to help Zambias efforts to fight AIDS
7. Acupuncture May Help Chemotherapy Side Effects
8. Chemotherapy Pill Has Fewer Side Effects Than IV
9. Therapy Boosts Chemotherapy Effects
10. Smoking and its Effects
11. Reducing The After Effects of Tonsillectomy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... 26, 2017 , ... Global healthcare company Novo Nordisk, renewed ... company’s commitment to the world’s first all-diabetes professional cycling team to a total ... partnered with the professional cycling team Team Type 1 to create Team Novo ...
(Date:9/26/2017)... ... September 26, 2017 , ... After a summer-long contest ... Campaign for Designated Drivers proudly announced the winners of the HEROtini Mocktail Challenge ... restaurants took on the challenge of competing in three categories: Best HEROtini Mocktail, ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... expands services in Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, ... Analysis (ABA) services. Aspire provides center based Autism services in Broomfield and will ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort ... “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation of published ... Hays Sate University, who has worked at a local mental health center for over ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: